Biotech Event Tracker

274 events

Date	Symbol	Description	Type	Disease	Designation	Success Rating
Q3 2016	TNXP	Tonix Pharmaceuticals (TNXP) Phase 3 Results of Tonmya for Sleep in Fibromyalgia	Phase 3 Results	Neurology	Special Protocol Assessment
05/11/2016	AAAP	Advanced Accelerator Applications (AAAP) Phase 3 Results of Lutathera for Neuroendocrine Tumors	Phase 3 Results	Oncology	Orphan Drug, Priority Review
11/30/2016	LXRX	Lexicon Pharmaceuticals (LXRX) PDUFA of Telotristat for Carcinoid Syndrome	510K Submission	Oncology	Orphan Drug, Priority Review
H2 2016	OXGN	OXiGENE (OXGN) Phase 2 Results of CA4P for Neuroendocrine Tumors	Phase 2 Results	Oncology	Orphan Drug
04/15/2016	CHMA	Chiasma (CHMA) PDUFA of Mycapssa for acromegaly	PDUFA	Endocrine	Orphan Drug
Q1 2017	CAPR	Capricor (CAPR) Phase 1/2 Results of CAP-1002 for Duchenne muscular dystrophy associated cardiomyopathy	Phase 1/2 Results	Other	Orphan Drug
05/09/2016	SPPI	Spectrum Pharmaceuticals (SPPI) PDUFA of Evomela for conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma	PDUFA	Oncology	Orphan Drug
H2 2016	ARRY	Array BioPharma (ARRY) Phase 3 Results of Selumetinib for KRAS-mutant Non-Small Cell Lung Cancer	Phase 3 Results	Oncology	Orphan Drug
H2 2016	RDHL	RedHill (RDHL) Phase 3 Results of RHB-104 for Chron's Disease	Phase 3 Results	Other	Orphan Drug
Q4 2016	KPTI	Karyopharm (KPTI) Phase 2/3 Results of Selinexor for Multiple Myeloma	Phase 2/3 Results	Oncology	Orphan Drug